CancerIQ

I had a great time speaking at the 2024 Social Determinants of Health & Health Equity Forum about our population health approach to cancer prevention and early detection. ICYMI, we talked about: - Why it’s time to abandon the one-size-fits-all approach to cancer prevention and ensure high-risk populations get the care they need to stay ahead of cancer. - How campaign-based risk assessment and digital tools can help healthcare providers meet patients where they are, without overloading clinical teams. - What communication strategies motivate patients to take action and proactively manage their individual cancer risk. To see this approach in action, join CancerIQ for a live webinar on July 18 at 2:30PM CT! Rachael Schmidt, APRN, Cancer Survivorship & Cancer Risk Prevention Program Director, and Assistant Director of Health Promotion & Screening, will share how Nebraska Medicine uses campaign-based risk assessment to drive cancer screening compliance and increase preventive service utilization. Sign up today: https://bit.ly/3XUuuYW #healthequity #aheadofcancer #precisionprevention

Project Purple® is now partnering with CancerIQ so the public can learn about Hereditary Cancer Risk by completing an online assessment. More information on who and why you should get screened is available as well. Knowledge is power and the sooner you find out about your risk the better your long term outcome could be. Click below for more details. #ScreeningSavesLives #PancreaticCancer #ProjectPurple

Serena gets her screening mammogram every year, but she only recently learned that all mammograms aren’t created equal. She was excited to learn her breast health clinic uses state-of-the-art tools paired with a breast-trained radiologist to help keep her as healthy as possible. Risk Evaluation: The risk assessment she took provides her physician guidance on creating a personalized care plan for her screenings. Image Quality: When the mammo tech takes the #mammogram scans, using #intelliMammo helps ensure the scans are as clear as possible so she won’t need to come back in for a rescan. AI Detection: When the #radiologist reads the scans, #ProFoundAI helps them evaluate any potential issues first, greatly increasing the chance of detecting breast cancer at the earliest possible stage, when outcomes are best. Learn More: https://bit.ly/45Hv264 #BreastAI, #BreastCancer, #EarlyDetection, #KnowYourRisk, CancerIQ, Densitas Inc.

Join us on July 18th 3:30PM ET/ 12:30PM PT to discover how Nebraska Medicine transformed their approach to cancer screening by implementing CancerIQ’s newest digital tools for targeted, campaign-based patient outreach. Easy-to-launch marketing strategies can help your organization capture high-risk patients and navigate them to hyper-personalized care prior to a diagnosis. Rachael Schmidt, APRN, Cancer Survivorship & Cancer Risk Prevention Program Director, and Assistant Director of Health Promotion & Screening, joins the CancerIQ team to discuss how she scaled her program, leading to significant increases in scheduled low-dose CT scans and preventive services. This successful model is now being replicated for colon cancer screening in GI specialties and employee wellness programs. Register below via LinkedIn or Visit: https://lnkd.in/e_Zt5w7C

Up next at the World Conference Forum 2024 Social Determinants of Health & Health Equity Forum at 4:15PM CT, Feyi Ayodele will take the stage for her session, "A Population Health Approach to Equitable Cancer Prevention and Early Detection." If you're a population health leader responsible for driving significant change but facing budget constraints, this session is for you! Feyi will be addressing the urgent need for health systems to improve risk stratification for tailored cancer prevention and detection. Join us to discover how CancerIQ democratizes access to cancer risk assessment by increasing compliance with cancer screening across diverse populations, proving that culturally tailored patient education drives better health outcomes. #AheadOfCancer #PrecisionPrevention

On Juneteenth, I took a moment to commemorate a day that has made so much possible for me. I unplugged. I celebrated with friends. I enjoyed the perfect summer weather by the lake in Chicago. I forgot to post. Although we have been free from the burden of slavery for nearly 200 years, I am deeply grateful for the choices people continue to make that shape my journey. I am thankful for my employees who choose to work for a Black woman with a big vision. I appreciate my investors who chose to invest in me, despite less than 1% of venture capital going to people who look like me. I am grateful for my customers who choose to do business with me and uphold their diversity supplier goals. And I am especially thankful for the hundreds of thousands of patients who benefit from our technology, which would not be possible without the end of slavery. Juneteenth is also a day for learning and reflection, and I want to share what drives me at CancerIQ . Despite many advances in oncology, too many people of color continue to die from cancer. African American women are 40% more likely to die of breast cancer than white women, and we are often diagnosed with more aggressive, harder-to-treat diseases at younger ages. The breast cancer death rate for Black women under 50 is twice that of white women. Simply put, when we’re diagnosed with cancer, we don’t win. It’s time for a different approach. Equitable cancer care begins when we recognize that every patient shouldn’t be treated the same because every patient’s risk isn’t the same. Full stop. That’s why I’m proud to say, in the spirit of Juneteenth, that we’re doing something dramatically different at CancerIQ. We are bringing cancer risk assessment out of the clinic to meet patients where they are and to maximize the reach of the genetics workforce. We are producing culturally tailored patient education to promote positive health behaviors. We are sensitive to the fact that “who communicates matters,” working with community health workers, and providing navigation services to populations who really can’t afford to get cancer. Stay tuned for more updates on the progress we're making to end cancer as we know it, for everyone.

This weekend at American Society of Clinical Oncology (ASCO), American Cancer Society CEO Karen Knudsen MBA PhD issued an important call to action: “Success looks like ending cancer as we know it — for everyone.” Her message was loud and clear: To accelerate progress against cancer, we must consider health equity in every program, solution and intervention. And the time to start is now. At CancerIQ, we could not agree more. Democratizing access to precision health has been in our DNA since the very beginning. Hearing ACS call attention to health equity at ASCO — on National Cancer Survivors Day no less — was a powerful reminder that we are not alone. From the drug companies developing new therapies to the advocacy groups amplifying patient needs to the providers engaging patients in genetic risk assessment and early detection, so many have committed their lives to helping others survive cancer. It was inspiring to be in the same room as so many others working to ensure everyone has the chance to be a survivor. Let’s continue that work, together. #ASCO #NationalCancerSurvivorsDay #NationalCancerSurvivorsMonth #AheadOfCancer

In the realm of cancer prevention and early detection, healthcare providers continually seek innovative ways to engage with and educate their communities. Beyond the traditional clinic setting, there lies a vast opportunity to connect with individuals who might not be aware of their cancer risk or the preventive measures they can take. CancerIQ's software comes with a full suite of services, including wraparound campaigns that are designed to engage specific populations for risk assesment through a variety of channels, including community events, social media, and direct patient outreach. Learn more: https://bit.ly/3KfHf8f #precisionprevention #aheadofcancer #campaignbasedriskassessment

CancerIQ is proud to announce that its co-founder and Chief Scientific Officer Dr. Olufunmilayo (Funmi) Olopade was awarded the 2024 Ellis Island Medal of Honor for her achievements in the field of cancer genetics and genomics. The Ellis Island Medal of Honor, one of the most prestigious awards in the country, recognizes Americans of immigrant descent who have made significant contributions to society. "I am really proud to work on a problem that is solvable. It is no longer acceptable to describe cancer disparities when we can use science and technology to save more lives," said Dr. Olopade. Her latest research, a watershed moment for population diversity in breast cancer genetics research, is the largest genome-wide association study (GWAS) of breast cancer in women of African descent conducted to date and identifies new genetic variants that have been shown to markedly reduce disparities in risk assessment models. Findings from this study were recently published by a team of scientists, including Dr. Olopade, in the peer-reviewed journal Nature Genetics. #precisionprevention #aheadofcancer

It was a pleasure to be back in Chicago for the 12th Annual International Clinical Cancer Genomics Conference, with local hosting by UChicago Medicine. Ever since I helped organize the first "bootcamp" in the series at City of Hope, this forum has always served as a cornerstone for learning about the latest research, technologies and interventions advancing the field of cancer genetics and genomics.   That’s why I was particularly excited to help announce the launch of the VALUE in Cancer Risk Programs Study at this year’s meeting alongside Feyi Ayodele. The VALUE study seeks to answer what I believe is one of the big questions holding back community-level precision health programs, and that is: what is the ROI of risk assessment program implementation for health systems?   Understanding the net financial benefit of cancer risk programs is especially salient given the economic challenges health systems face today. It is our hope that demonstrating the opportunity in digitally enabled cancer risk programs will translate to more widespread adoption of precision cancer prevention, early detection and treatment.    For this research effort, I will be working in partnership with CancerIQ as a scientific advisor for a project to document the downstream revenue of digital interventions for genetically informed cancer care. We are currently seeking health systems to participate — so if would like to learn more or join the study, let’s connect – shoot me a message and I’ll put you in touch with the CIQ team.